Athena Neurosciences
Executive Summary
South San Francisco-based CNS drug firm files an NDA for Zanaflex (tizanidine) for the treatment of spasticity of spinal cord origin associated with multiple sclerosis and spinal cord injury. The oral agent is licensed from Sandoz, which markets the drug in over 25 countries. Zanaflex is Athena's first NDA filing.